

Accepted as poster #P367 at the World Congress on Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases, April 19-22, 2018, Krakow, Poland

SM04690, a Wnt Pathway Inhibitor: Anti-Inflammatory and Cartilage Protective Effects in Preclinical OA Models

Vishal Deshmukh, Tim Seo, Christopher Swearingen, and Yusuf Yazici

Samumed, LLC, San Diego, CA, USA

Objectives: Osteoarthritis (OA) is characterized by pain, swelling, and reduced function in the knee joint. Upregulated Wnt signaling drives OA through synovial inflammation, increased subchondral bone, and thinning cartilage. SM04690, a small molecule Wnt pathway inhibitor that demonstrated chondrogenic and anti-inflammatory properties preclinically¹, was further evaluated to determine its potential to reduce inflammation, protect cartilage, improve joint health and modify pain in OA.

Material and methods: Cytokine secretion (IL-6 and TNF- α) from IL-1 β -stimulated and SM04690-treated synovial fibroblasts was measured by ELISA. A single intra-articular injection of SM04690 or vehicle was evaluated in an *in vivo* rat knee monosodium iodoacetate (MIA) OA model. Joint inflammation was evaluated by H&E staining, inflammatory cytokines (IL-1 α , IL-1 β , IL-6, TNF- α and IFN- γ) by qPCR, and cartilage protection by qPCR for matrix metalloproteinases (MMPs). Histological evaluation of cartilage health was performed using OARSI score and thickness by Safranin-O staining. Pain was measured as paw withdrawal threshold using Von Frey apparatus and weight distribution using incapacitance meter and analyzed using generalized estimating equation regression.

Results: SM04690 dose-dependently inhibited IL-1 β -induced cytokine secretion in synovial fibroblasts (EC₅₀ ~30 nM; Fig.1). In the rat MIA OA model, compared to vehicle, SM04690 injection reduced visible knee swelling, inflammatory cells, and proinflammatory cytokine and MMP production (p<0.05). SM04690 increased (p<0.01) paw withdrawal threshold from Day 6 and improved weight distribution to the affected limb in treated rats, at multiple timepoints, compared to vehicle (Fig.2). SM04690 increased Safranin-O stained cartilage thickness and decreased OARSI score (p<0.05) compared to vehicle.

Conclusions: In a rat MIA OA model, SM04690 injection reduced inflammation, protease production, and pain, with improved cartilage and joint health, compared to vehicle. Previously demonstrated regenerative effects in nonclinical studies¹, along with anti-inflammatory properties, show SM04690 may improve symptoms and potentially provide disease modification in OA. Clinical studies are ongoing.

Reference: ¹Deshmukh et al. *Osteoarthritis Cartilage* 2017.

Figure 1. SM04690 inhibited inflammatory cytokine production in synovial fibroblasts *in vitro*




Figure 2. SM04690 inhibited inflammatory cytokine production and decreased inflammation and pain in the MIA model of OA

